3,007 Gilead Sciences, Inc. $GILD Shares Sold by Profund Advisors LLC

Profund Advisors LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 107,861 shares of the biopharmaceutical company’s stock after selling 3,007 shares during the period. Profund Advisors LLC’s holdings in Gilead Sciences were worth $16,077,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of Nova Scotia purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at about $100,056,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Gilead Sciences during the second quarter worth about $55,754,000. Groupe la Francaise raised its stake in Gilead Sciences by 30.9% during the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock worth $6,270,000 after acquiring an additional 11,712 shares in the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Gilead Sciences by 3.6% during the second quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after purchasing an additional 10,206 shares during the period. Finally, Headlands Technologies LLC purchased a new position in Gilead Sciences in the second quarter valued at about $6,251,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Gilead Sciences Price Performance

GILD stock opened at $170.68 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. Gilead Sciences, Inc. has a 52 week low of $114.02 and a 52 week high of $175.65. The firm has a market cap of $211.63 billion, a P/E ratio of -54.01 and a beta of 0.31. The firm’s fifty day moving average is $150.87 and its 200 day moving average is $139.79.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.70%. The company had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter last year, the firm earned $2.47 earnings per share. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. Research analysts predict that Gilead Sciences, Inc. will post -1.03 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. Gilead Sciences’s dividend payout ratio is presently -103.80%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the sale, the insider directly owned 118,234 shares in the company, valued at $16,273,727.76. This represents a 19.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the completion of the transaction, the chief executive officer directly owned 577,133 shares in the company, valued at $85,785,049.12. This trade represents a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 111,000 shares of company stock worth $15,877,860. Insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on GILD. Needham & Company LLC set a $175.00 price objective on shares of Gilead Sciences in a research report on Friday. BMO Capital Markets reaffirmed an “outperform” rating and issued a $184.00 price target on shares of Gilead Sciences in a research report on Friday. TD Cowen raised their price target on Gilead Sciences from $160.00 to $175.00 and gave the company a “buy” rating in a report on Friday. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $185.00 price target on shares of Gilead Sciences in a research report on Friday, October 23rd. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $169.19.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.